Everything below concerns dihexa. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
== Clinical significance == Tumorigenesis in mammary glands can be induced biochemically by abnormal expression level of circulating hormones or local ECM components, or from a mechanical change in the tension of mammary stroma. Under either of the two circumstances, mammary epithelial cells would grow out of control and eventually result in cancer. Almost all instances of breast cancer originate in the lobules or ducts of the mammary glands.
== Phylogeny == The Ecdysozoa include the following phyla: Arthropoda, Onychophora, Tardigrada, Kinorhyncha, Priapulida, Loricifera, Nematoda, and Nematomorpha. A few extinct taxa have been classified as stem group ecdysozoans, such as Uncus dzaugisi and Acosmia. Other groups such as the gastrotrichs, have been considered possible members but lack the main characters of the group, and are now placed elsewhere. The Arthropoda, Onychophora, and Tardigrada have been grouped together as the Panarthropoda because they are distinguished by segmented body plans. Dunn et al. in 2008 suggested that the tardigrada could be grouped along with the nematodes, leaving Onychophora as the sister group to the arthropods. The non-panarthropod members of Ecdysozoa have been grouped as Cycloneuralia but they are more usually considered paraphyletic in representing the primitive condition from which the Panarthropoda evolved. A modern consensus phylogenetic tree for Ecdysozoa is shown below, mainly based on the one supported by Giribet & Edgecombe (2017), which summarizes relationships found in recent ecdysozoan phylogenies:
In other countries, such as Egypt, it is legal to use and purchase tobacco products regardless of age. Germany raised the purchase age from 16 to 18 on September 1, 2007. Some police departments in the United States occasionally send an underaged teenager into a store where cigarettes are sold, and have the teen attempt to purchase cigarettes, with their own or no ID. If the vendor then completes the sale, the store is issued a fine. Similar enforcement practices are regularly performed by Trading Standards officers in the UK, and by equivalents in Israel and the Republic of Ireland.
Sources: en.wikipedia.org
==== MeSH D12.776.210.500.570 – myogenic regulatory factors ==== MeSH D12.776.210.500.570.590 – myod protein MeSH D12.776.210.500.570.595 – myogenic regulatory factor 5 MeSH D12.776.210.500.570.600 – myogenin
== Adverse effects == Although avanafil is generally well tolerated, dose dependent adverse effects can occur. The most common adverse effects include headache, flushing, nasopharyngitis, nasal congestion, and back pain. While it is also uncommon, there is a potential for visual disturbances to occur in patients, as well as hearing impairment.
=== Acquisitions === In 1989, after a four-month legal dispute to avoid a takeover, Church's Chicken became the second-largest chicken restaurant chain when it was acquired by Popeyes for $330 million. The acquisition court documents stated that Church's Chicken would close 250 of its restaurants, "keep 92 with the Church's name, rename 303 others as Popeyes and sell 440 others for about $160 million over the next four years". Merrill Lynch and a group of banks led by Canadian Imperial financed the acquisition. In 1992, Popeyes' parent company, Al Copeland Enterprises, Inc., was forced to file chapter 11 bankruptcy for the more than $400 million debt it owed its creditors for the Church's Chicken buyout. In 1993, Al Copeland Enterprises, Inc. was renamed AFC Enterprises, Inc., or America's Favorite Chicken, and became the parent company of Church's Chicken and Popeyes. In 2004, Arcapita bought Church's Chicken from AFC Enterprises, Inc., and former Domino's Pizza and Little Caesars executive Harsha Agadi became president and CEO of Church's Chicken. In 2005, because Arcapita invests in companies that respect Shari'ah principles, it removed pork products from the Church's Chicken menu. In 2007, AFC Enterprises, Inc. filed a lawsuit against Church's Chicken and former franchise group CVI Company, for allegedly colluding to breach Popeyes' franchise, development and guaranty agreements with CVI, when "Church's [Chicken] bought all 10 of CVI's Popeyes' restaurants and converted most of them to the Church's Chicken brand".
=== Osteoconduction === Osteoconduction is termed as "the property of a material to support tissue ingrowth, osteoprogenitor cell growth, and development for bone formation to occur". In the context of bone grafting it occurs when the bone graft material serves as a scaffold for new bone growth that is perpetuated by the native bone. Osteoblasts from the margin of the defect that is being grafted utilize the bone graft material as a framework upon which to spread and generate new bone. Osteoblasts do not originate from the donor tissue, but through the internal ingrowing of the host's cells. The proper bonding of bioactive chemicals (Beta-Tricalcium Phosphate) in implants used in bone grafting surgery allow the promotion of osteoconductivity in the area of a defect. In the very least, a bone graft material should be osteoconductive by being made up of these bioactive chemicals.
Sources: en.wikipedia.org
== Album information == Wolf Hoffmann explained the concept behind the album: "We had read an article that someone was working on an artificial heart and that one day everybody is going to have a computerized heart. It talked, in general terms, about how more and more of humanity gets sucked out of daily life and more and more replaced by machines. It's not a new thing now, but then it was new. Humans versus machine was the general vibe of the record." The original cover concept was for a hologram of a metal heart until budget considerations resulted in a traditional cover. But fittingly for the futuristic theme of the album, Metal Heart was the first Accept album to be digitally mastered. Hoffmann recalls Dieter Dierks as a very demanding producer: "We would do some pieces several dozen times trying to capture what he had in his mind for a specific section," adding: "Each song we tried different combinations of guitars, mic'ing and even strings!" The song "Metal Heart" is well known for containing the cover of two famous classical themes: Tchaikovsky's "Slavonic March" (in the intro) and Beethoven's "Für Elise" in the main riff and solo. This song was covered in 1998 by Norwegian black metal band Dimmu Borgir for their album Godless Savage Garden. "I had no idea it would become as popular as it did," Hoffmann remembers of his contribution to the song. "Midnight Mover", about a drug dealer, is one of the more commercial songs on the album and was selected for a music video that anticipates the bullet time filming technique by a full decade.
Reduced food waste: Of all the food calories produced in a year, 25% are wasted between on-farm production and consumers. Traceability systems facilitate better identification of supply-side weaknesses, such as where and how much food is lost downstream of the farm. Emerging digital innovations, such as milk cartons that track milk from "farm to fridge," can address demand-side waste by providing consumers with more accurate expiration dates. Consumer trust: Ensuring food safety, quality, and authenticity has become an important regulatory requirement in high-income countries. Use of RFID tags and blockchain technologies to certify agri-food products' characteristics could provide near-real-time quality signals to consumers. Improved producer welfare: Producers who can leverage environmental certification could sell their products at a premium, because blockchain technologies could enable greater trust in labels like "sustainable," "organic" or "fair trade."
A dismissal for redundancy means that a job is no longer economically necessary for an employer's operations. To ensure the power of dismissal is not misused, the law attempts to ensure that the social costs of unemployment and dislocation are factored into the employer's decisions. Under the Fair Work Act 2009 section 531(2), employers must consult with unions if they contemplate that 15 or more jobs could be redundant, and under section 530 the employer must also give written notice to Centrelink of any proposals. The goal of the law is to avoid job losses, and so under section 531(3) the employer must consult unions on proposals on "measures to avert or minimise the proposed dismissals", alternative employment or mitigating adverse effects of proposed redundancies. If redundancies must take place, the National Employment Standard in section 119 requires minimum redundancy payments of at least 4 weeks' pay for employees that have worked over 1 year to 16 weeks' pay for people with at least 9 years' work, while those over 10 years' work may take advantage of long service leave and redundancy pay. However, employees can not take redundancy if they have been offered an acceptable alternative job. There are also a series of arbitrary exceptions to redundancy rights. Employees of employers with under 15 staff get nothing, on the theory that small businesses need protection more than workers. Casual, trainee and weekly fixed term employees are also excluded from protection, even though this means around 22% of the Australian workforce.
=== Psychotropic effects === Bromantane is described primarily as a mild stimulant and anxiolytic. It is also said to possess anti-asthenic properties. Bromantane is reported to improve physical and mental performance, hence it could be considered a performance-enhancing drug. Bromantane has been found to lower the levels of pro-inflammatory cytokines IL-6, IL-17 and IL-4 and to normalize behavior in animal models of depression, and may possess clinical efficacy as an antidepressant. It has also been found to increase sexual receptivity and proceptivity in rats of both sexes, which was attributed to its dopaminergic actions. It has been proposed that bromantane may suppress prolactin levels by virtue of its dopaminergic properties as well. Bromantane has been found to "agonize" amphetamine-induced stereotypies in vivo, suggesting that it might potentiate certain effects of other stimulants. The stimulant effects of bromantane onset gradually within 1.5–2 hours and last for 8–12 hours when taken orally.
Aminothiazole (2-thiazolamine) (1) is condensed with 2-acetylbutyrolactone [517-23-7] (2) under DS-trap until the water has separated. Condensation of this β-keto lactone can be visualized to involve initial attack on the reactive butyrolactone by the primary nitrogen; cyclodehydration of that hypothetical intermediate 3 gives 6-(2-hydroxyethyl)-7-methyl-[1,3]thiazolo[3,2-a]pyrimidin-5-one, CID:82612453 (4). Halogenation of the terminal alcohol with phosphorus oxychloride then yields 6-(2-chloroethyl)- 7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one, [86488-00-8] (5). Alkylation with 4-(bis(4-fluorophenyl)methylene)piperidine, [58113-36-3] (6) would complete the synthesis of ritanserin (7).
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.